Skip to search formSkip to main contentSkip to account menu

CP 690,550

Known as: CP-690550, CP-690,550, CP690550 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tofacitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma
Extranodal, nasal-type natural killer (NK)/T-cell lymphoma (NKCL) is an aggressive malignancy with poor prognosis in which… 
Highly Cited
2012
Highly Cited
2012
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
BACKGROUND Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally… 
Highly Cited
2012
Highly Cited
2012
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
UNLABELLED The molecular pathogenesis of natural killer/T-cell lymphoma (NKTCL) is not well understood. We conducted whole-exome… 
Highly Cited
2012
Highly Cited
2012
Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
In this Phase 2b study, 331 low‐to‐moderate risk de novo kidney transplant patients (approximately 60% deceased donors) were… 
Review
2009
Review
2009
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
Pfizer Inc is developing the novel JAK3 inhibitor CP-690550 for the potential prevention of transplant rejection and treatment of… 
Highly Cited
2009
Highly Cited
2009
Calcineurin‐Inhibitor‐Free Immunosuppression Based on the JAK Inhibitor CP‐690,550: A Pilot Study in De Novo Kidney Allograft Recipients
This randomized, pilot study compared the Janus kinase inhibitor CP‐690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each… 
Highly Cited
2008
Highly Cited
2008
The specificity of JAK3 kinase inhibitors.
PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for… 
Highly Cited
2005
Highly Cited
2005
Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates
Background. Janus kinase 3 (JAK3) mediates signal transduction from cytokine receptors using the common chain (&ggr;c). Because… 
Highly Cited
2004
Highly Cited
2004
The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models
JAK‐3 has been shown to play a key role in cytokine signaling via γc, e.g. IL‐2, 4, 7, 9, 15, 21. The current study describes the… 
Highly Cited
2003
Highly Cited
2003
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)